Peptide comparisons
75 head-to-head comparisons, each with a verdict and the dimensions that actually differ. Only 20 pairs have been tested against each other in a published trial; the rest compare separate studies and labels, and say so.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
GLP-1 and incretin agonists
| Comparison | Verdict | Direct trials |
|---|---|---|
| Cagrilintide vs pramlintide | Verdict: it depends on the goal | 0 |
| Dulaglutide vs exenatide | Verdict: favors dulaglutide | 1 |
| Dulaglutide vs mazdutide | Verdict: it depends on the goal | 2 |
| Dulaglutide vs retatrutide | Verdict: it depends on the goal | 1 |
| Liraglutide vs cagrilintide | Verdict: it depends on the goal | 1 |
| Victoza vs Trulicity | Verdict: it depends on the goal | 1 |
| Liraglutide vs exenatide | Verdict: favors liraglutide | 2 |
| Liraglutide vs setmelanotide | Verdict: it depends on the goal | 0 |
| Mazdutide vs retatrutide | Verdict: it depends on the goal | 0 |
| Retatrutide vs survodutide | Verdict: favors retatrutide | 0 |
| CagriSema vs semaglutide | Verdict: favors semaglutide | 1 |
| Ozempic vs Trulicity | Verdict: favors semaglutide | 1 |
| Semaglutide vs exenatide | Verdict: favors semaglutide | 1 |
| Wegovy vs Saxenda | Verdict: favors semaglutide | 1 |
| Semaglutide vs mazdutide | Verdict: it depends on the goal | 1 |
| Semaglutide vs retatrutide | Verdict: favors semaglutide | 0 |
| Semaglutide vs setmelanotide | Verdict: it depends on the goal | 0 |
| Semaglutide vs survodutide | Verdict: favors semaglutide | 1 |
| Wegovy vs Zepbound | Verdict: it depends on the goal | 2 |
| Survodutide vs mazdutide | Verdict: favors mazdutide | 0 |
| CagriSema vs tirzepatide | Verdict: favors tirzepatide | 0 |
| Mounjaro vs Trulicity | Verdict: favors tirzepatide | 2 |
| Zepbound vs Saxenda | Verdict: favors tirzepatide | 0 |
| Tirzepatide vs mazdutide | Verdict: favors tirzepatide | 0 |
| Retatrutide vs tirzepatide | Verdict: favors tirzepatide | 0 |
| Tirzepatide vs survodutide | Verdict: favors tirzepatide | 0 |
We may earn a commission from these links.
Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.
Tissue repair and healing
| Comparison | Verdict | Direct trials |
|---|---|---|
| BPC-157 vs ARA-290 (cibinetide) | Verdict: favors ARA-290 (cibinetide) | 0 |
| BPC-157 vs GHK-Cu | Verdict: favors GHK-Cu | 0 |
| BPC-157 vs KPV | Verdict: it depends on the goal | 0 |
| BPC-157 vs TB-500 | Verdict: it depends on the goal | 0 |
| Follistatin-344 vs ACE-031 (ramatercept) | Verdict: favors ACE-031 (ramatercept) | 0 |
| IGF-1 LR3 vs PEG-MGF | Verdict: favors IGF-1 LR3 | 0 |
| KPV vs LL-37 | Verdict: it depends on the goal | 0 |
| TB-500 vs GHK-Cu | Verdict: favors GHK-Cu | 0 |

BPC-157 oral
from Bodybuilding Peptides
Partner lists from $242/month
Longevity and mitochondrial
| Comparison | Verdict | Direct trials |
|---|---|---|
| Carnosine vs glutathione | Verdict: favors carnosine | 0 |
| Epitalon vs MOTS-c | Verdict: it depends on the goal | 0 |
| Epitalon vs thymalin | Verdict: it depends on the goal | 0 |
| Glutathione vs NAD+ | Verdict: it depends on the goal | 0 |
| MOTS-c vs humanin | Verdict: it depends on the goal | 0 |
| MOTS-c vs SS-31 (elamipretide) | Verdict: favors SS-31 (elamipretide) | 0 |
| NAD+ vs MOTS-c | Verdict: favors NAD+ | 0 |
Cognitive and neuroprotective
| Comparison | Verdict | Direct trials |
|---|---|---|
| Cerebrolysin vs Semax | Verdict: favors cerebrolysin | 0 |
| Dihexa vs Semax | Verdict: favors Semax | 0 |
| P21 vs Dihexa | Verdict: favors P21 | 0 |
| Pinealon vs epitalon | Verdict: favors epitalon | 0 |
| Selank vs Noopept | Verdict: it depends on the goal | 0 |
| Semax vs Noopept | Verdict: favors Semax | 0 |
| Semax vs Selank | Verdict: it depends on the goal | 0 |

Semax nasal spray
from Bodybuilding Peptides
Partner lists from $188/month
Sexual health and reproductive
| Comparison | Verdict | Direct trials |
|---|---|---|
| HCG vs gonadorelin | Verdict: favors HCG | 1 |
| HCG vs kisspeptin-10 | Verdict: favors HCG | 0 |
| Kisspeptin-10 vs gonadorelin | Verdict: favors gonadorelin | 1 |
| Melanotan I (afamelanotide) vs Melanotan II | Verdict: favors Melanotan I (afamelanotide) | 0 |
| PT-141 (bremelanotide) vs Melanotan II | Verdict: favors PT-141 (bremelanotide) | 0 |
| PT-141 vs oxytocin | Verdict: favors PT-141 | 0 |
Metabolic and growth hormone axis
| Comparison | Verdict | Direct trials |
|---|---|---|
| AOD-9604 vs 5-Amino-1MQ | Verdict: it depends on the goal | 0 |
| AOD-9604 vs semaglutide | Verdict: favors semaglutide | 0 |
| CJC-1295 vs ipamorelin | Verdict: favors CJC-1295 | 0 |
| GHRP-2 vs GHRP-6 | Verdict: favors GHRP-2 | 0 |
| Hexarelin vs GHRP-2 | Verdict: it depends on the goal | 1 |
| Ipamorelin vs GHRP-6 | Verdict: it depends on the goal | 1 |
| Ipamorelin vs MK-677 (ibutamoren) | Verdict: it depends on the goal | 0 |
| Sermorelin vs CJC-1295 | Verdict: favors sermorelin | 0 |
| Sermorelin vs ipamorelin | Verdict: favors sermorelin | 0 |
| Sermorelin vs MK-677 (ibutamoren) | Verdict: favors sermorelin | 0 |
| Sermorelin vs tesamorelin | Verdict: favors tesamorelin | 0 |
| Tesamorelin vs CJC-1295 | Verdict: favors tesamorelin | 0 |
| Tesamorelin vs ipamorelin | Verdict: favors tesamorelin | 0 |
| Tesamorelin vs MK-677 (ibutamoren) | Verdict: favors tesamorelin | 0 |
| Tesamorelin vs retatrutide | Verdict: it depends on the goal | 0 |
| Tesofensine vs semaglutide | Verdict: favors semaglutide | 0 |
Immune and antimicrobial
| Comparison | Verdict | Direct trials |
|---|---|---|
| Thymosin alpha-1 vs TB-500 | Verdict: favors thymosin alpha-1 | 0 |
| Thymosin alpha-1 vs thymulin | Verdict: favors thymosin alpha-1 | 0 |
Other peptides
| Comparison | Verdict | Direct trials |
|---|---|---|
| Leuprolide vs degarelix | Verdict: it depends on the goal | 1 |
| Octreotide vs lanreotide | Verdict: it depends on the goal | 0 |
| Teriparatide vs abaloparatide | Verdict: it depends on the goal | 1 |
Verdicts weigh the published evidence and labels, not personal suitability. See the peptide index, the cost index, and the methodology.



